Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213531 · ClinicalTrials.gov registry record
Enhanced Valves Interventions and Safe AI Generated End Results
A clinical trial of Heart Valve Disease and TAVI, sponsored by Montreal Heart Institute.
- Recruiting
- Registry status
- 21,000
- Enrollment target
- 15
- Study locations
NCT07213531: Recruiting study of Heart Valve Disease and TAVI, sponsored by Montreal Heart Institute.
NCT07213531 is a study of Heart Valve Disease and TAVI that is actively recruiting participants, run by Montreal Heart Institute. The registered enrollment target is 21,000 participants. The trial reports 15 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07213531, a study of Heart Valve Disease and TAVI, is actively recruiting participants, sponsored by Montreal Heart Institute.
- RECRUITING
- Registry status
- 21,000 participants
- Enrollment target
- 15
- Study locations
Study Summary
This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.
Primary Outcome
Validation of artificial intelligence algorithms for automatic segmentation of anatomic structures and imaging measurements, and prediction of the success of transcatheter interventions. Output of AI algorithm: * Sizes, types, and number of devices to be implanted * Device success * Percentage risk of permanent pacemaker implantation (for TAVI and TTVI) * Percentage risk of 30-day (para)valvular regurgitation for TAVI, and residual regurgitation for M-TEER and T-TEER * Single leaflet detachmen
Interventions
- DIAGNOSTIC_TEST Medical imaging analysis via artificial intelligence algorithms
Study Locations (15)
Other
- St Michael's Hospital Toronto - Toronto
- St Paul's Hospital Vancouver - Vancouver
- Centre Hospitalier Universitaire (CHU) de Bordeaux, 12 rue Dubernat 33404 Talence cedex - Bourdeaux
- CHU Lille - Lille
- CHU Marseille - Marseille
- Centre Cardiologique du Nord Paris - Paris
- Institut Cardiovasculaire Paris-Sud Paris - Paris
- Centre Hospitalier Universitaire Rennes - Rennes
- Clinque Pasteur Toulouse - France - Toulouse
- University Medical Center Hamburg-Eppendorf - Hamburg
- Heart Valve Center Mainz - Mainz
- Istituto Clinico Città di Brescia - Brescia
- San Raffaele Heart Valve Center Milan - Milan
New York
- Montefiore Medical Center New York - New York
Quebec
- Montreal Heart Institute, 5000 Rue Bélanger, Montréal - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21,000 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2029-05 |
What NCT07213531 shows while recruiting
NCT07213531 is an observational study that tracks outcomes without assigning an intervention. Its 21,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 8 conditions, with Heart Valve Disease appearing as the primary indexed condition, and to 1 intervention - of which Medical imaging analysis via artificial intelligence algorithms is the first listed.
NCT07213531 lists 15 locations in 3 states (Other, New York, Quebec).
Frequently Asked Questions
What is clinical trial NCT07213531 about?
NCT07213531 is a clinical study titled "Enhanced Valves Interventions and Safe AI Generated End Results". This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.
What is the current status of trial NCT07213531?
This trial is currently recruiting. The enrollment target is 21,000 participants. The study started on 2024-05-01. Estimated completion is 2029-05.
What conditions does trial NCT07213531 study?
This clinical trial studies the following conditions: Heart Valve Disease, TAVI, M-TEER, TTVI, TMVI.
What interventions are being tested in trial NCT07213531?
The interventions under investigation include: Medical imaging analysis via artificial intelligence algorithms (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07213531?
This trial is sponsored by Montreal Heart Institute, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213531 being conducted?
This trial has 15 study locations across New York, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Valve Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06047041 · 21,350 participants · NA
Implementation Supports for Improving Identification and Delivery of School-based Mental Health Supports for Middle Schools Students
- NCT06062342 · 20,400 participants · NA
Five Point Initiative: A Bundled Implementation Strategy to Address the HIV Epidemic in Black Communities
- NCT05832307 · 22,000 participants · NA
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI